Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modrapac005
- Development stage
- Unknown
- Lead developer
- Modra Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
ModraPac005 is a novel oral formulation of paclitaxel developed by Modra Pharmaceuticals. It is designed to be administered orally, often in combination with a boosting agent (ritonavir), to improve the pharmacokinetics and tolerability compared to traditional intravenous paclitaxel. Paclitaxel is a member of the taxane class of chemotherapeutic agents and acts primarily as a tubulin inhibitor, disrupting microtubule function and thereby inhibiting cell division in cancer cells. The oral formulation aims to address limitations associated with IV administration such as hospital-based infusions and excipient-related toxicities. ModraPac005/r has been investigated for use in various solid tumors[1][2][3].
- Other names
- ModraPac005ModraPac-005ModraPac 005MP5MP-5MP 5
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on modrapac005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modrapac005.